- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00162123
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
28 giugno 2016 aggiornato da: Bristol-Myers Squibb
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.
In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.
Panoramica dello studio
Tipo di studio
Interventistico
Iscrizione (Effettivo)
248
Fase
- Fase 2
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Buenos Aires, Argentina, CP1280AEB
- Local Institution
-
-
-
-
-
Wels, Austria, A-4600
- Local Institution
-
Wien, Austria, 1090
- Local Institution
-
-
-
-
-
Brussels, Belgio, 1090
- Local Institution
-
Brussels, Belgio, 1070
- Local Institution
-
Bruxelles, Belgio, 1200
- Local Institution
-
-
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasile, 90610
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brasile, 90050
- Local Institution
-
-
Sao Paulo
-
Jau, Sao Paulo, Brasile, 17210
- Local Institution
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Local Institution
-
Edmonton, Alberta, Canada, T6G 1Z2
- Local Institution
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1C 6Z8
- Local Institution
-
-
-
-
-
Aarhus C, Danimarca, 8000
- Local Institution
-
-
-
-
-
St. Petersburg, Federazione Russa, 191104
- Local Institution
-
Stavropol, Federazione Russa, 355047
- Local Institution
-
Voronezh, Federazione Russa, 394000
- Local Institution
-
-
-
-
-
Brest, Francia, 29200
- Local Institution
-
Lyon Cedex 08, Francia, 69373
- Local Institution
-
Paris, Francia, 75010
- Local Institution
-
Vandoeuvre Les Nancy, Francia, 54511
- Local Institution
-
-
-
-
-
Berlin, Germania, D-12200
- Local Institution
-
Heidelberg, Germania, 69120
- Local Institution
-
Kiel, Germania, D-24105
- Local Institution
-
-
-
-
-
Jerusalem, Israele, 91120
- Local Institution
-
Tel-Aviv, Israele, 64239
- Local Institution
-
-
-
-
-
Genova, Italia, 16132
- Local Institution
-
Meldola (Fc), Italia, 47014
- Local Institution
-
Rimini, Italia, 47900
- Local Institution
-
Siena, Italia, 53100
- Local Institution
-
-
-
-
-
Oslo, Norvegia, 0310
- Local Institution
-
-
-
-
-
Lodz, Polonia, 90553
- Local Institution
-
Poznan, Polonia, 61-866
- Local Institution
-
Wroclaw, Polonia, 51-124
- Local Institution
-
-
-
-
-
Olomouc, Repubblica Ceca, 775 20
- Local Institution
-
-
-
-
-
Malaga, Spagna, 29010
- Local Institution
-
Valencia, Spagna, 46009
- Local Institution
-
-
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85719
- University of Arizona Cancer Center
-
-
California
-
Laverne, California, Stati Uniti, 91750
- Wilshire Oncology Medical Group Inc
-
Los Angeles, California, Stati Uniti, 90033
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, Stati Uniti, 90025
- The Angeles Clinic & Research Inst.
-
San Francisco, California, Stati Uniti, 94115
- San Francisco Oncology Associates
-
-
Connecticut
-
To come, Connecticut, Stati Uniti
- Local Institution
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32207
- Baptist Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Indiana Oncology Hematology Consultants
-
-
Missouri
-
Saint Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
St Joseph, Missouri, Stati Uniti, 64507
- St Joseph Oncology Inc
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28203
- Carolinas Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- The Christ Hospital Cancer Center Research
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97213
- Providence Portland Medical Center
-
-
South Carolina
-
Greenville, South Carolina, Stati Uniti, 29615
- Cancer Centers of the Carolinas
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75230
- Center For Oncology Research & Treatment, P.A.
-
Lubbock, Texas, Stati Uniti, 79410
- Joe Arrington Cancer Research and Treatment Center
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- University of Washington Medical Center
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Sud Africa, 2199
- Local Institution
-
-
Western Cape
-
Cape Town, Western Cape, Sud Africa, 7570
- Local Institution
-
-
-
-
-
Dnepropetrovsk, Ucraina, 49044
- Local Institution
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Key Inclusion Criteria
- Diagnosis of advanced melanoma
- Prior treatment in a prespecified prior/parent ipilimumab study
- Men and women 18 years of age and older
First Reinduction:
- No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation
- Had experienced documented progressive disease after expanded clinical benefit
Extended Maintenance
- Received ipilimumab at any dose in a parent study
- Achieved expanded clinical benefit at the time of entry to current study
Follow-up:
- Received ipilimumab at any dose in a closing parent study
- Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up
Key Exclusion Criteria
- Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
- Primary ocular or mucosal melanoma
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: First reinduction: Ipilimumab, 0.3 to 10 mg/kg
Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Altri nomi:
|
|
Sperimentale: First reinduction: Ipilimumab, 3 to 10 mg/kg
Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Altri nomi:
|
|
Sperimentale: First reinduction: Ipilimumab, 10 to 10 mg/kg
Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Altri nomi:
|
|
Sperimentale: Extended maintenance: Ipilimumab, 0.3 mg/kg
Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Altri nomi:
|
|
Sperimentale: Extended maintenance: Ipilimumab, 3 mg/kg
Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Altri nomi:
|
|
Sperimentale: Extended maintenance: Ipilimumab, 10 mg
Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Altri nomi:
|
|
Nessun intervento: Follow-up
Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With On-study Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related AEs, Immune-related AEs (irAEs), and Death as Outcome
Lasso di tempo: Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
An SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Drug-related is defined as having certain, probable, possible, or missing relationship to study drug.
An IrAE is an AE characterized by a potential association with inflammation and considered by the investigator to be drug related.
Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
|
Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: From first dose of study drug in parent study to death or date of last censoring.
|
OS was computed for all patients who entered this study and is defined as the time between the first dose of study therapy and death.
If a patient has not died, OS was censored at the time of last contact.
|
From first dose of study drug in parent study to death or date of last censoring.
|
|
Percentage of Participants Surviving at 1, 1.5, and 2 Years
Lasso di tempo: From first dose of study drug in parent study to up to 2 years after reinduction
|
Survival rate was defined as the time from first dose of study drug to 1, 1.5, and 2 years.
|
From first dose of study drug in parent study to up to 2 years after reinduction
|
|
Number of Participants With On-study Immune-related Adverse Events (irAEs)
Lasso di tempo: From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
irAEs were defined as adverse events characterized by a potential association with inflammation and considered by the investigator as drug related.
These prespecified terms were grouped into the following organ-specific subcategories: gastrointestinal, hepatic, skin, endocrine, neurologic, and other (includes blood, eye, immune system, investigations, infections, renal, and respiratory systems).
Patients may have 1 or more events.
|
From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
|
Progression-free Survival (PFS)
Lasso di tempo: From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
PFS was defined as the time between the date of the baseline tumor assessment in this study and the date of progression or death, whichever occurred first.
|
From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Collegamenti utili
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 maggio 2006
Completamento primario (Effettivo)
1 settembre 2012
Completamento dello studio (Effettivo)
1 aprile 2014
Date di iscrizione allo studio
Primo inviato
9 settembre 2005
Primo inviato che soddisfa i criteri di controllo qualità
9 settembre 2005
Primo Inserito (Stima)
13 settembre 2005
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
27 luglio 2016
Ultimo aggiornamento inviato che soddisfa i criteri QC
28 giugno 2016
Ultimo verificato
1 giugno 2016
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Tumori neuroendocrini
- Nevi e melanomi
- Melanoma
- Meccanismi molecolari dell'azione farmacologica
- Agenti antineoplastici
- Agenti antineoplastici, immunologici
- Inibitori del checkpoint immunitario
- Ipilimumab
Altri numeri di identificazione dello studio
- CA184-025
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .